等待开盘 02-07 09:30:00 美东时间
+0.270
+7.03%
Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising approval delay concerns despite the review remaining active.
01-10 00:28
U.S. stocks traded higher this morning, with the Dow Jones index gaining around...
01-09 23:25
Aquestive Therapeutics announced that the FDA has accepted their New Drug Application (NDA) for Anaphylm™ to treat Type 1 allergic reactions, including anaphylaxis, with a PDUFA target action date of January 31, 2026. Anaphylm, if approved, would be the first and only orally delivered epinephrine option in the U.S., offering a device-free, portable solution for patients.
2025-06-16 11:00
Lake Street analyst Thomas Flaten maintains Aquestive Therapeutics (NASDAQ:AQST) with a Buy and lowers the price target from $10 to $8.
2025-03-08 05:11
北京时间2025年01月29日03时15分,Sonoma Pharmaceuticals, Inc.(SNOA.us)股票出现异动,股价大幅拉升5.07%。截至发稿,该股报2.77美元/股,成交量2.1868万股,换手率1.63%,振幅4.97%。 最近的财报数据显示,该股实现营业收入3.58百万美元,净利润-610000.00美元,每股收益-0.59美元,毛利1.36百万美元,市盈率-2.80倍。 机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。 Sonoma Pharmaceuticals, Inc.股票所在的制药行业中,整体跌幅为0.38%...
2025-01-29 03:15